936954-10-8

Basic information

• Product Name: 4-chloro-7-ethoxy-6-nitroQuinazoline
• Synonyms: 4-chloro-7-ethoxy-6-nitroQuinazoline
• CAS NO: 936954-10-8
• Molecular Formula: C₁₀H₈ClN₃O₃
• Molecular Weight: 253.64182
• Mol File: 936954-10-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 430.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.455±0.06 g/cm3(Predicted)
• PKA: 0.53±0.70(Predicted)
• CAS DataBase Reference: 4-chloro-7-ethoxy-6-nitroQuinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-7-ethoxy-6-nitroQuinazoline(936954-10-8)
• EPA Substance Registry System: 4-chloro-7-ethoxy-6-nitroQuinazoline(936954-10-8)

Safety Data

• Hazardous Substances Data: 936954-10-8(Hazardous Substances Data)

Upstream product

• 53449-14-2 7-Chloro-6-nitro-quinazolin-4-one 

Downstream Products

• 1360430-59-6 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)acrylamide 
• 1360430-60-9 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-(dimethylamino)propanamide 
• 1360430-71-2 3-chloro-N-(4-(3-Chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)propanamide 
• 1360430-61-0 N-(4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl)-3-piperidin-1-ylpropanamide 
• 1360430-62-1 N-(4-((3-chloro-4-fluorophenyl)amino)-7-ethoxyquinazolin-6-yl)-3-morpholinopropanamide 
• 1269662-90-9 N⁴-(3-chloro-4-fluorophenyl)-7-ethoxyquinazoline-4,6-diamine 
• 1360430-70-1 N-(3-chloro-4-fluorophenyl)-7-ethoxy-6-nitroquinazoline-4-amine 

Relevant articles and documents

Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides

Irreversible epidermal growth factor receptor (EGFR) inhibitors contain a reactive warhead which covalently interacts with a conserved cysteine residue in the kinase domain. The acrylamide fragment, a commonly employed warhead, effectively alkylates Cys797 of EGFR, but its reactivity can cause rapid metabolic deactivation or nonspecific reactions with off-targets. We describe here a new series of irreversible inhibitors containing a 3-aminopropanamide linked in position 6 to 4-anilinoquinazoline or 4-anilinoquinoline-3- carbonitrile driving portions. Some of these compounds proved to be as efficient as their acrylamide analogues in inhibiting EGFR-TK (TK = tyrosine kinase) autophosphorylation in A549 lung cancer cells. Moreover, several 3-aminopropanamides suppressed proliferation of gefitinib-resistant H1975 cells, harboring the T790M mutation in EGFR, at significantly lower concentrations than did gefitinib. A prototypical compound, N-(4-(3-bromoanilino)quinazolin-6- yl)-3-(dimethylamino)propanamide (5), did not show covalent binding to cell-free EGFR-TK in a fluorescence assay, while it underwent selective activation in the intracellular environment, releasing an acrylamide derivative which can react with thiol groups.